Abstract 3901
Background
Efficacy data of treatment sequences in mRCC are rare. In the Czech Republic, data on efficacy and safety of all targeted therapies for mRCC are collected in the RENIS patient registry. Thus, RENIS provides data from the real-world clinical practice. The aim of this study was to compare outcomes of selected treatment sequences in mRCC while adjusting for differences in patient characteristics using inverse propensity score weighting method (IPWS).
Methods
Data of mRCC patients treated using most common treatment sequences were collected in RENIS between 06/2007 and 02/2018. Overall survival (OS) and progression free survival (PFS) were evaluated. Baseline characteristics were balanced using IPWS. The propensity score was evaluated with nominal logistic model to balance Eastern Cooperative Oncology Group (ECOG) performance status, time from diagnosis to first treatment, nephrectomy, Memorial Sloan-Kettering Cancer Center (MSKCC) score, and age. Median and confidence intervals (CI) were derived from IPWS weighted Kaplan-Meier curves that were compared using log-rank test.
Results
Overall, 745 patients in five treatment sequences were included and analysed. Differences in OS were significant (p < 0.001) with sunitinib→axitinib→everolimus and sunitinib→axitinib sequences associated with improved survival over other sequences. These differences could be also linked to time when these drugs were introduced. PFS did not differ between sunitinib and pazopanib used as first line treatments (p = 0.44) but the PFS in the second line differed significantly (p = 0.035) (Table). Table: Results of OS and PFS for examined sequences computed using inverse propensity score weighting. Sunitinib → Axitinib → Everolimus sequence should be assessed with caution due to immortal time bias.Table: 892P
| Parameter | Treatment sequence | n | Median | 95% CI for median | p | |
|---|---|---|---|---|---|---|
| Lower limit | Upper limit | |||||
| OS (months) | Sunitinib → Everolimus | 312 | 26.3 | 23.8 | 29.0 | <0.001 |
| Sunitinib → Axitinib | 154 | 47.6 | 31.3 | 50.5 | ||
| Sunitinib → Axitinib → Everolimus† | 114 | 46.0 | 44.7 | 50.9 | ||
| Pazopanib → Everolimus | 74 | 32.9 | 30.9 | 33.8 | ||
| Pazopanib → Sunitinib | 91 | 27.2 | 26.7 | 28.8 | ||
| PFS 1st line (months) | Sunitinib | 580 | 10.2 | 9.8 | 10.8 | 0.440 |
| Pazopanib | 165 | 9.2 | 8.5 | 10.0 | ||
| PFS 2nd line (months) | Sunitinib → Everolimus | 312 | 5.8 | 5.1 | 6.3 | 0.035 |
| Sunitinib → Axitinib | 268 | 6.4 | 6.0 | 7.1 | ||
| Pazopanib → Everolimus | 74 | 5.1 | 4.1 | 5.5 | ||
| Pazopanib → Sunitinib | 91 | 5.3 | 5.1 | 7.1 |
Conclusions
Improved outcomes were associated with sequences using second-line axitinib over those using second-line sunitinib or everolimus in a cohort of patients from a national registry.
Clinical trial identification
Legal entity responsible for the study
Jindrich Finek.
Funding
Value Outcomes.
Editorial Acknowledgement
Disclosure
J. Finek: Honoraria: Amgen, BMS, Roche, Bayer, Teva, MSD, Merck, Sanofi, Pierre Fabre. R. Demlova: Honoraria for lectures: Bayer. K. Kopeckova: Honoraria for lectures: Novartis; Travel grants: Pfizer, Bayer. T. Buchler: Honoraria for advisory boards and/or lectures: Novartis, Pfizer, Bayer, Roche. B. Melichar: Honoraria for advisory boards and/or lectures: Novartis, Pfizer, Glaxo Smith Kline, Roche, Bayer. A. Poprach: Honoraria for lectures: Novartis, Bristol-Myers Squibb, Roche, Bayer. T. Hrnciarova, T. Mlcoch, T. Dolezal: Employee of Value Outcomes. All other authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract